AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches

Biomarker Testing in NSCLC:
Biomarker testing is crucial in non-small cell lung cancer (NSCLC) to inform clinical decisions. NCCN Guidelines recommend testing for EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, HER2, and PD-L1 expression status in eligible patients.

Actionable Biomarkers:
Actionable biomarkers in NSCLC include EGFR, ALK, BRAF V600E, HER2, KRAS G12C, MET exon 14 skipping, NTRK1/2/3, PD-L1, RET, and ROS1. These biomarkers can be targeted by FDA-approved treatments.

Emerging Biomarkers:
High-level MET amplification is an emerging biomarker in metastatic NSCLC. Novel prognostic and predictive biomarkers like STK11, KEAP1, and SMARCA4 are being researched to better inform treatment planning.

Clinical Trials:
AstraZeneca is conducting clinical trials, such as the HUDSON study and the Phase 2 platform study (D6186C00001), to explore biomarker-directed targeted therapies and immunotherapies in NSCLC patients.

Treatment Strategies:
AstraZeneca is refining its NSCLC treatment strategies with biomarker-driven approaches, including combination therapies like osimertinib with savolitinib, alectinib, or selpercatinib, and exploring the use of durvalumab in various combinations.

Recent Developments:
AstraZeneca presented data at the 2023 World Conference on Lung Cancer (WCLC) showcasing its robust lung cancer portfolio and pipeline, including results from the FLAURA2 Phase III trial and updates on Enhertu, Imfinzi, and datopotamab deruxtecan.